Zobrazeno 1 - 10
of 137
pro vyhledávání: '"Jürgen Wollenhaupt"'
Autor:
Philip J. Mease, Dafna D. Gladman, Juan J. Gomez‐Reino, Stephen Hall, Arthur Kavanaugh, Eric Lespessailles, Georg Schett, Maria Paris, Nikolay Delev, Lichen Teng, Jürgen Wollenhaupt
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 8, Pp 459-470 (2020)
Objective Psoriatic arthritis (PsA) requires long‐term treatment, yet safety concerns and monitoring requirements make maintenance a challenge. This analysis of pooled Psoriatic Arthritis Long‐term Assessment of Clinical Efficacy (PALACE) 1, 2, a
Externí odkaz:
https://doaj.org/article/fa93086f13fa47d6bce83b4a9731f08f
Autor:
Jürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis, Joel Silverfield, Ketti Terry, Koshika Soma, Chris Mojcik, Ryan DeMasi, Sander Strengholt, Kenneth Kwok, Irina Lazariciu, Lisy Wang, Stanley Cohen
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-18 (2019)
Abstract Background Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA). Method
Externí odkaz:
https://doaj.org/article/cbd75ed150f44a9ea233626add2ba876
Autor:
Peter Nash, Yoshiya Tanaka, Kevin L Winthrop, Eun Bong Lee, Xavier Mariette, Jeffrey R Curtis, Kenneth Kwok, Connie Chen, Pinaki Biswas, Lisy Wang, Christina Charles-Schoeman, Ann Madsen, Stanley B Cohen, Andrea Shapiro, Jürgen Wollenhaupt
Publikováno v:
RMD Open, Vol 6, Iss 3 (2020)
Objective Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term e
Externí odkaz:
https://doaj.org/article/06d315c88fb8416d89479fa698afb87f
Autor:
Kevin L, Winthrop, Yoshiya, Tanaka, Eun Bong, Lee, Jürgen, Wollenhaupt, Ahmad, Al Enizi, Valderilio F, Azevedo, Jeffrey R, Curtis
Publikováno v:
Clinical and Experimental Rheumatology. 40:162-172
The risk of herpes zoster (HZ) and HZ-related complications is increased in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) relative to the general population; therefore, HZ vaccination is recommended in these patient groups. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef3cdde8ba845faa47d244a043f90aba
https://doi.org/10.55563/clinexprheumatol/cpu6r9
https://doi.org/10.55563/clinexprheumatol/cpu6r9
Autor:
Ara Dikranian, David Gold, Louis Bessette, Peter Nash, Valderilio F. Azevedo, Lisy Wang, John Woolcott, Andrea B. Shapiro, Annette Szumski, Dona Fleishaker, Jürgen Wollenhaupt
Publikováno v:
Rheumatology and Therapy. 9:411-433
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). This post hoc analysis assessed frequency or duration of early select non-serious adverse events (AEs; excluding infections),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff0c595f4cde4cf75df392de3276e724
https://doi.org/10.1007/s40744-021-00405-w
https://doi.org/10.1007/s40744-021-00405-w
Autor:
Alexander Pfeil, Martin Krusche, Fabian Proft, Diana Vossen, Jürgen Braun, Xenofon Baraliakos, Michael N. Berliner, Gernot Keyßer, Andreas Krause, Hanns-Martin Lorenz, Bernhard Manger, Florian Schuch, Christof Specker, Jürgen Wollenhaupt, Anna Voormann, Martin Fleck
Publikováno v:
Zeitschrift für Rheumatologie.
Zusammenfassung Hintergrund In den nächsten Jahren gehen viele Haus- bzw. Fachärzt:innen in den Ruhestand. Wie in anderen Disziplinen stellt sich in der Rheumatologie die Frage, ob ausreichend Weiterbildungsstellen zur Verfügung stehen, um das Ver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3fd6af81e6eb4199a7155a0ce8d98cc
https://doi.org/10.1007/s00393-022-01284-4
https://doi.org/10.1007/s00393-022-01284-4
Autor:
Alexander, Pfeil, Martin, Krusche, Fabian, Proft, Diana, Vossen, Jürgen, Braun, Xenofon, Baraliakos, Michael N, Berliner, Gernot, Keyßer, Andreas, Krause, Hanns-Martin, Lorenz, Bernhard, Manger, Florian, Schuch, Christof, Specker, Jürgen, Wollenhaupt, Anna, Voormann, Martin, Fleck
Publikováno v:
Zeitschrift fur RheumatologieLiteratur.
In the next few years many general practitioners and specialists will retire. As in other disciplines the question arises in rheumatology whether sufficient training positions are available to maintain or expand the supply of care according to demand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2a3d99e76892b555984a461611782b33
https://pubmed.ncbi.nlm.nih.gov/36264331
https://pubmed.ncbi.nlm.nih.gov/36264331
Autor:
Stanley Cohen, Sander Strengholt, Kenneth Kwok, Lisy Wang, Robert Landewé, Ketti Terry, Désirée van der Heijde, Jürgen Wollenhaupt
Publikováno v:
Rheumatology (Oxford, England), 60(4), 1708-1716. Oxford University Press
Rheumatology (Oxford, England)
Rheumatology, 60(4), 1708-1716. OXFORD UNIV PRESS
Rheumatology (Oxford, England)
Rheumatology, 60(4), 1708-1716. OXFORD UNIV PRESS
Objectives Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We evaluated radiographic progression in tofacitinib-treated patients with RA for up to 3 years in two pooled long-term extension (LTE) studies (ORAL Sequel; A3921041)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce8014682414cc39460e4bc0d0510fa9
https://doi.org/10.1093/rheumatology/keaa476
https://doi.org/10.1093/rheumatology/keaa476
Autor:
Juan J. Gomez-Reino, Stephen Hall, Philip J. Mease, Georg Schett, N. Delev, Dafna D. Gladman, L. Teng, Eric Lespessailles, Jürgen Wollenhaupt, Maria Paris, Arthur Kavanaugh
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 8, Pp 459-470 (2020)
ACR Open Rheumatology
ACR Open Rheumatology, 2020, ⟨10.1002/acr2.11156⟩
ACR Open Rheumatology
ACR Open Rheumatology, 2020, ⟨10.1002/acr2.11156⟩
OBJECTIVE Psoriatic arthritis (PsA) requires long-term treatment, yet safety concerns and monitoring requirements make maintenance a challenge. This analysis of pooled Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) 1, 2, and 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af41e432a10f189798b6e0b38a4874d5
https://doaj.org/article/fa93086f13fa47d6bce83b4a9731f08f
https://doaj.org/article/fa93086f13fa47d6bce83b4a9731f08f
Autor:
Jeffrey L. Kaine, Liza Takiya, Ryan DeMasi, Vara Bandi, Jürgen Wollenhaupt, Haiyun Fan, M. Snyder, Koshika Soma, John Tesser, Lisy Wang
Publikováno v:
Clinical Rheumatology
Introduction/objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post-hoc analysis evaluated the effect of temporary discontinuation and reinitiation of tofacitinib on disease control in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::863c7061a85c30ce5bc635c6a91805f6
https://doi.org/10.1007/s10067-020-04956-1
https://doi.org/10.1007/s10067-020-04956-1